成都华健未来科技

Huajian Future is a clinical-stage biotechnology company based in Chengdu, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in metabolic diseases, oncology, and aging-related conditions. Leveraging its proprietary drug discovery platform, Huajian Future has advanced a pipeline of candidates, including its lead program HJ-001, a potent AMPK activator currently in Phase 1 trials for NASH. The company integrates advanced medicinal chemistry with AI-driven technologies to accelerate the development of next-generation treatments. Huajian Future aims to provide high-quality, affordable innovative drugs for patients worldwide.